TNIK

Across TCGA pan-cancer cohorts, TNIK mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TNIK data layer compared with 23 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TNIK mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated TNIK expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where TNIK mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	II,III,IV	0.944	0.761	.003	51	view →
CCRCC	DFS	Tertile	II,III,IV	0.794	0.980	.035	10	view →
LUAD	OS	Quartile	III,IV	0.848	0.378	.007	6	view →
LSCC	OS	Tertile	II,III,IV	0.886	1.000	.035	3	view →
GBM	DFS	Quartile	All	0.511	0.284	.013	3	view →
UCEC	OS	Median	All	0.962	0.844	.034	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TNIK–PDAC (OS)

Open the PDAC breakdown →